Caster Semenya launches final bid to save career and defend Olympic title

Two-time Olympic champion Caster Semenya is to take her case against World Athletics regulations which bar her from competing in some events to the European Court of Human Rights.

Semenya has twice lost legal challenges against the rule, which dictates that she must take medication to lower her natural testosterone level to compete in women’s races from 400metres up to a mile. Both of Semenya’s Olympic golds, as well as her three world titles, have come over 800m.

The South African’s lawyers say there has been a “violation of her rights” and are urging the the human rights court to examine the rules.

Semenya has one of a number of conditions known as differences of sex development. Although she has never publicly released details of her condition, World Athletics has controversially referred to her as “biologically male” in previous legal proceedings, a description that angered Semenya.

Semenya has the typical male XY chromosome pattern and levels of testosterone that are much higher than the typical female range, World Athletics says. The track and field body says that gives her and other athletes like her an unfair advantage over other female runners.

The 30-year-old was legally identified as female at birth and has identified as female her whole life. She says her testosterone is merely a genetic gift.

The regulations have been fiercely criticised, mainly because of the “treatment” options World Athletics gives to allow affected athletes to compete. They have one of three options to lower their testosterone levels: taking daily contraceptive pills, using hormone-blocking injections, or having surgery.

“The regulations require these women to undergo humiliating and invasive physical examinations followed by harmful and experimental medical procedures if they wish to compete internationally in women’s events between 400m and one mile, the exact range in which Ms. Semenya specialises,” Semenya’s lawyers said.

Similar Articles

Comments

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular